Clinical relevance of findings in trials of antipsychotics: Systematic review

British Journal of Psychiatry

Volumn 198, Issue 5, 2011, Pages 341-345

  Lepping, Peter ^a   Sambhi, Rajvinder S ^b   Whittington, Richard ^c   Lane, Steven ^d   Poole, Rob ^a  

^a GLYNDWR UNIVERSITY   (United Kingdom)

^b BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Centre for Medical Statistics and Health Evaluation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZUCLOPENTHIXOL;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG EFFICACY; DRUG SCREENING; HUMAN; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 79955535003     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.109.075366     Document Type: Review

References (18)

1. Davis JM, Leucht S, Glick ID. CATIE findings revisited. Psychiatr Serv 2009; 60: 125-6.
2. Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv 2008; 59: 523-5.
3. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 2007; 191: 82-3. (Pubitemid 47035186)
4. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a metaanalysis. Lancet 2009; 3: 31-41.
5. Swartz MS, Stroup TS, McEvoyJP, Davis SM, Rosenheck RA, Keefe RS, et al. What CATIE found: results from the schizophrenia trial. Psychiatr Serv 2008; 59: 500-6.
6. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUTLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87. (Pubitemid 44498387)
7. Levine SZ, Rabinowitz J, Engel R, Etschel E, Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr Res 2008; 98: 318-22. (Pubitemid 350235891)
8. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean? Schizophr Res 2005; 79: 231-8. (Pubitemid 41457263)
9. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 2005; 187: 366-71. (Pubitemid 41442390)
10. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second- generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64. (Pubitemid 36682312)
11. Jäger M, Riedel M, Obermeier M, Schennach-Wolff R, Seemüller F, Messer T, et al. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients. Schizophr Res 2010; 118: 183-8.
12. Eack SM, Newhill CE, Anderson CM, Rotondi AJ. Quality of life for persons living with schizophrenia: more than just symptoms. Psychiatr Rehabil J 2007; 30: 219-22. (Pubitemid 46106790)
13. Kinon BJ, Chen L, Asher-Svanum H, Stauffer VL, Kollack-Walker S, Sniadecki JL, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008; 102: 230-40.
14. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 2009; 438: 7-14.
15. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006; 113: 91-5. (Pubitemid 43348370)
16. Andreasen NC, Carpenter Jr WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-9. (Pubitemid 40343909)
17. Opler MG, Yang LH, Caleo S, Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 2007; 7: 35.
18. Leucht S, Kissling W, Davis JM. The PANSS should be rescaled. Schizophr Bull 2010; 36: 461-2.